Loading clinical trials...

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

A Phase 1/2 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkin's Lymphoma

NCT00299494•Pfizer

View on ClinicalTrials.gov

Summary

The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin \[CMC-544\] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects with CD20 and CD22-positive, follicular or diffuse large B-cell NHL who have not responded or progressed after 1 or 2 prior therapies; or subjects with CD20 and CD22-positive intermediate/aggressive NHL (diffuse large B-cell, mantle cell, transformed follicular or follicular grade 3b NHL) who have not responded or progressed after 1 or more prior therapies and are refractory to a previous rituximab containing therapy.
•Prior therapy must contain at least one course of rituximab therapy, as single agent or in combination.
•Measurable disease.

Exclusion Criteria

•Subjects who are candidates for other potentially curative therapies.
•Subjects must not have received previous radioimmunotherapy.
•Subjects who have undergone a prior bone marrow transplantation within the last 6 months.

Locations (38)

University of Alabama at Birmingham-

Birmingham, Alabama, United States

IDS Pharmacy

Birmingham, Alabama, United States

University of Alabama at Birmingham-

Birmingham, Alabama, United States

California Cancer Care, Inc.

Greenbrae, California, United States

University of California Medical Center

San Francisco, California, United States

California Cancer Care

San Mateo, California, United States

Emory Clinic

Atlanta, Georgia, United States

Emory University Hospital

Atlanta, Georgia, United States

Emory University Investigational Drug Service

Atlanta, Georgia, United States

Northwestern Medical Faculty Foundation

Chicago, Illinois, United States

Key Dates

Start Date

May 4, 2006

Primary Completion Date

May 19, 2014

Completion Date

June 2, 2014

Last Updated

March 8, 2018

Enrollment

119

ACTUAL participants

Conditions

B-Cell Lymphoma

Interventions

inotuzumab ozogamicin

DRUG

inotuzumab ozogamicin

DRUG

inotuzumab ozogamicin

DRUG

Rituximab

DRUG

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

DLBCLDiffuse Large B-Cell Lymphoma

View study

RECRUITINGPHASE1

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

NCT06026319

Non-hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 8, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Inclusion Criteria

Exclusion Criteria

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

A Long-term Extension Study of PCI-32765 (Ibrutinib)

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma